$0.671091
0.022.44%
Last update: 2:06 PM
15 minutes delayed
Comments
Loading...
Vincerx Pharma
VINCNASDAQ
Vincerx Pharma (NASDAQ:VINC) Stock, Analyst Ratings, Price Targets, Forecasts
Vincerx Pharma Inc has a consensus price target of $17 based on the ratings of 7 analysts. The high is $30 issued by Laidlaw & Co. on September 13, 2021. The low is $3 issued by Chardan Capital on November 17, 2022. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Chardan Capital, and SVB Leerink on September 7, 2023, November 17, 2022, and August 12, 2022, respectively. With an average price target of $4.33 between Cantor Fitzgerald, Chardan Capital, and SVB Leerink, there's an implied 556.17% upside for Vincerx Pharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
SVB Leerink
B. Riley Securities
HC Wainwright & Co.
Laidlaw & Co.
1calculated from analyst ratings
Analyst Ratings for Vincerx Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | — | Cantor Fitzgerald | Li Watsek | — | Reiterates | → Overweight | Get Alert |
| 09/07/2023 | Buy Now | 657.12% | Cantor Fitzgerald | Li Watsek | → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 11/17/2022 | Buy Now | 354.27% | Chardan Capital | Matthew Barcus | $4 → $3 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | 657.12% | SVB Leerink | Jonathan Chang | $6 → $5 | Maintains | Outperform | Get Alert |
| 06/08/2022 | Buy Now | 1111.39% | Cantor Fitzgerald | Li Watsek | $22 → $8 | Maintains | Overweight | Get Alert |
| 06/07/2022 | Buy Now | 808.54% | B. Riley Securities | Kalpit Patel | $12 → $6 | Maintains | Buy | Get Alert |
| 06/07/2022 | Buy Now | 505.69% | Chardan Capital | Matthew Barcus | $11 → $4 | Maintains | Buy | Get Alert |
| 06/07/2022 | Buy Now | 808.54% | SVB Leerink | Jonathan Chang | $19 → $6 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | 1565.66% | Chardan Capital | Matthew Barcus | $14 → $11 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | 2777.04% | SVB Leerink | Jonathan Chang | $20 → $19 | Maintains | Outperform | Get Alert |
| 03/30/2022 | Buy Now | 2928.47% | SVB Leerink | Jonathan Chang | $24 → $20 | Maintains | Outperform | Get Alert |
| 03/30/2022 | Buy Now | 4139.85% | HC Wainwright & Co. | Michael King | $25 → $28 | Maintains | Buy | Get Alert |
| 01/14/2022 | Buy Now | 3685.58% | HC Wainwright & Co. | Michael King | → $25 | Initiates | → Buy | Get Alert |
| 12/23/2021 | Buy Now | 3685.58% | Cantor Fitzgerald | Li Watsek | → $25 | Initiates | → Overweight | Get Alert |
| 11/01/2021 | Buy Now | 3534.16% | SVB Leerink | Jonathan Chang | — | Initiates | → Outperform | Get Alert |
| 09/13/2021 | Buy Now | 4442.7% | Laidlaw & Co. | Yale Jen | — | Initiates | → Buy | Get Alert |
| 08/25/2021 | Buy Now | 3837.01% | B. Riley Securities | Kalpit Patel | — | Initiates | → Buy | Get Alert |
| 08/13/2021 | Buy Now | 4442.7% | Chardan Capital | Geulah Livshits | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Vincerx Pharma (VINC) stock?
The latest price target for Vincerx Pharma (NASDAQ:VINC) was reported by Cantor Fitzgerald on April 9, 2024. The analyst firm set a price target for $0.00 expecting VINC to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vincerx Pharma (VINC)?
The latest analyst rating for Vincerx Pharma (NASDAQ:VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.
When was the last upgrade for Vincerx Pharma (VINC)?
There is no last upgrade for Vincerx Pharma
When was the last downgrade for Vincerx Pharma (VINC)?
There is no last downgrade for Vincerx Pharma.
When is the next analyst rating going to be posted or updated for Vincerx Pharma (VINC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.
Is the Analyst Rating Vincerx Pharma (VINC) correct?
While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $0.00. The current price Vincerx Pharma (VINC) is trading at is $0.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.